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Abstract
Melanoma is the most aggressive, therapy-resistant skin cancer. The mammalian target of rapamycin (mTOR), the serine/
threonine kinase which integrates both intracellular and extracellular signals, plays a crucial role in coordinating the balance
between the growth and death of cells. The object of this study is a comparison of the influence of mTOR inhibitor everolimus in
the concentration range between 20 nM and 10 μM, used individually and in combination with selected downstream protein
kinases inhibitors: LY294002 (PI3K), U0126 (ERK1/2), AS-703026 (MEK) and MK-2206 (AKT) on the expression of pro-
survival proteins: p-Bcl-2 (S70), p-Bcl-2 (T56), Bcl-2, Bcl-xL, Mcl-1, activity of caspase-3, proliferation and induction of
apoptosis in melanoma cells. Current results clearly show that the nanomolar concentration of the mTOR inhibitor everolimus
in combination with the inhibitor of MAP kinase (AS-703026) or AKT kinase (MK-2206) is effective in inducing apoptosis and
reducing proliferation of melanoma cells. The herein research results confirm the hypothesis on the important role of mTOR
signaling in cancer progression, and gives hope that implementation of successful combination of its inhibitors will find
recognition and application in cancer treatment in the near future.
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Introduction
Apoptosis, or programmed cell death, plays an important role in
controlling number of cells in many developmental and physi-
ological processes and in oncotherapy-induced killing of cancer
cells (Galluzzi et al. 2018). It is a structured, genetically regu-
lated biological process guided by the ratio of pro-apoptotic and
anti-apoptotic proteins (Hu and Kavanagh 2003).
In particular anticancer therapies, it is important to under-
stand the mechanisms associated with cell death as it is be-
lieved that besides inhibition of tumour growth and cell inva-
sion, the effectiveness of anticancer therapy depends mainly
on its ability to induce apoptosis in cancer cells (Pfeffer and
Singh 2018).
The mTOR protein is a serine/threonine protein kinase
consisting of two complexes: mTORC1 and mTORC2. The
mTORC1 complex activates two best characterized down-
stream effectors: S6 ribosomal kinase1 (S6K1) and eukaryotic
initiation factor 4E-binding protein 1 (4E-BP1), and initiates
translation of key proteins for regulation of metabolism and
processes that are fundamental to cell growth, proliferation,
cell cycle and autophagy (Watanabe et al. 2011; Paquette et al.
2018). It seems that the basic function of the TORC2 complex
is cytoskeletal organization and regulation of cell survival and
invasion (Kim et al. 2017).
Dysregulation or stimulation of PI3K-AKT and mTOR
pathway plays a significant role in oncogenesis (Yang et al.
2017; Li et al. 2018). Overexpression of proteins of this path-
way, and intensified intracellular signal transduction have
been confirmed in numerous types of cancer including breast,
ovarian, prostate, gastric, kidney, bladder, melanoma, hepato-
cellular carcinoma (Kim et al. 2017; Ruzzolini et al. 2017;
Conciatori et al. 2018), and tumours of hematological origin,
such as acute leukemia, mantle cell lymphoma, Hodgkin’s
disease or multiple myeloma (Barrett et al. 2012).
Large-scale randomized trials have demonstrated that
everolimus prolongs survival of patients with solid cancers,
such as advanced breast cancer, renal cell carcinoma, and
several kinds of neuroendocrine tumour (Lin et al. 2016;
Kim et al. 2017; Li et al. 2018). Literature data Weeber et al.
(2017) also suggest that the benefits of everolimus-based ther-
apy depend on the genetic status of mutations in B-RAF and
Phosphatase and Tensin Homolog (PTEN). The loss of
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function or aberration of PTEN is associated with the success
of treatment, while B-RAF wild type could be responsible for
the resistance. PTEN status may potentially affect the choice
of clinical treatment and require reduced agent doses, thereby
reducing toxicity in combined inhibition of the MEK/ERK,
PI3K/AKT and mTOR pathways (Sathe et al. 2018). Limited
anti-tumour effects of mTOR inhibitors (rapalogs), may be
related to the induction of signaling feedback loops
(Conciatori et al. 2018; Sathe et al. 2018]. In view of the
above, the simultaneous blocking of both signaling pathways
– PI3K/AKT and mTOR – can be an effective therapeutic
strategy on account of promoting prolonged AKT, S6K1 and
4E-BP1 dephosphorylation and induction of apoptosis
(Conciatori et al. 2018; Sathe and Nawroth 2018).
Literature data (Kim et al. 2017) and our own results
(Ciołczyk-Wierzbicka and Laidler 2018; Ciołczyk-
Wierzbicka et al. 2018) suggest that mTOR inhibitors – both
rapamycin and everolimus – have significant impact on cell
cycle regulation, reduction of cell proliferation and invasive-
ness of melanoma cells (Ciołczyk-Wierzbicka and Laidler
2018; Ciołczyk-Wierzbicka et al. 2018). They also inhibit
expression of anti-apoptotic protein as well as induce apopto-
sis and autophagy (Kim et al. 2017).
Since many current studies searching for effective antican-
cer treatment focus their efforts on new capabilities of the
already registered drugs and their use in combination with
other potential ones, the herein study focuses on the effects
of protein kinase inhibitors, and in particular the very promis-
ing mTOR inhibitor everolimus, on expression of pro-survival
Bcl-2 family proteins, caspase-3 activity, and induction of
apoptosis in melanoma cells.
Materials and methods
Cell culture
Human melanoma cell lines: primary WM115 (VGP) and
metastatic: WM266–4 (derived from metastatic site – right
thigh skin). These cells lines feature the specific V600D mu-
tation in the B-RAF gene, as well as express PTEN loss of
function including hemizygous deletion and wild type for N-
ras, c-KIT and CDK4. Cells were cultured in RPMI-1640
medium supplemented with 10% fetal bovine serum and an-
tibiotics: penicillin and streptomycin. Cells were incubated at
37 °C in a humidified atmosphere of 5%CO2 in air. Cells were
treated with inhibitors of: 1/AKT – MK-2206 (Selleck) at
2 μM concentration, 2/ MEK – AS-703026 (Selleck) at
10 μM concentration, 3/ PI3K – LY294002 (Cell Signalling
TM) at 20 μM concentration, 4/ ERK1/2 – U0126 (Cell
Signalling TM) at 10 μM concentration, and 5/ mTOR –
everolimus (Selleck) at: 20 nM, 2 μM, 5 μM and 10 μM
concentrations. The incubation time of melanoma cells with
inhibitors were 24 and 48 h. Cells were obtained from the
ESTDAB Melanoma Cell Bank (Tubingen, Germany).
Caspase-3 activation assay
Activation of caspase-3 in response to applied inhibitors was
estimated by means of fluorogenic substrate DEVD-AFC
(Biovision). The cells were seeded in 24-well plates
(5*104cell/well). After 24 h growth period, they were treated
with individual selected inhibitors or their combinations, as well
as with vehicle (DMSO) as control. After respective incubation
time, the cells were lysed in lysis buffer (50-mM Tris-HCl,
pH 7.6, 100-mM NaCl, 1-mM EDTA, 1% Triton X-100) and
incubated (1,5 h; RT) with fluorogenic substrate (20 mmol/l
Ac-DEVD-AFC). To stop the reaction, the inhibitor of
caspase-3 activity (200 nM/l DEVD-CHO) was added, and
the amount of AFC released during incubation was measured
by means of spectrofluorometer (Hitachi-2000; λex = 400 nm
and λem = 505 nm). The signal corresponding to the caspase-3
activity was normalized to the cell number (determined using
the violet crystal test) and reported as fold increase of DEVD-
like caspase-3 activity in relation to control sample.
DNA fragmentation ELISA assay
Apoptosis induction was verified by assessment of the
intracellular level of cytoplasmic histone-associated-
DNA-fragments – Cell Death Detection ELISA Plus
(11,774,425,001 ROCHE) according to the manufac-
turer’s protocol.
The cells were briefly seeded on 96 wells plate, grown for
24 h and then treated with selected inhibitors, either individual
or in combinations, as well as with vehicle (DMSO) as the
control. After the incubation period, the cell culture medium
was discarded, the cells were lysed, and the lysates were cen-
trifuged in order to eliminate intact cell nuclei. Next, the su-
pernatant with histone-linked DNA fragments was applied on
streptavidin-coated microplate well, incubated with
immunoreagent, and then treated with a substrate to receive
colorimetric signal (A405; BIO-TEK Synergy HT Plate
Reader). The results are presented as mean absorbance value
(405 nm) which reflects the amount of mono- and
oligonucleosomes released to the cytoplasm of apoptotic cells.
Furthermore, as per the manufacturer’s instruction, the enrich-
ment factor (EF) was calculated to estimate the fold increase
of DNA fragmentation in the treated samples with reference to
the control one.
Cell proliferation
The proliferation of cells was assessed with the crystal
violet test as previously described (Ciołczyk-Wierzbicka
et al. 2012).
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Cytotoxicity assay
Cytotoxicity of selected kinases’ inhibitors: AKT –MK-2206
(2 μM), MEK – AS-703026 (10 μM), PI3K – LY294002
(20 μM), ERK1/2 – U0126 (10 μM), mTOR – everolimus
(20 nM, 2 μM, 5 μM and 10 μM) was determined using
Cytotoxicity Detection Kit LDH (Roche, Germany).
Western blot analysis
Samples for SDS-PAGE electrophoresis were prepared in the
same way as previously described (Ciołczyk-Wierzbicka et al.
2012). Antibodies against Phospho-Bcl-2 (Ser70) (SH2)
#2827, Phospho-Bcl-2 (Thr56) #2875, Bcl-2 (D55G8)
4223#, Bcl-xl (54H6) 2764#, Mcl-1 (D35A5) 5453# (Cell
Signaling Technology), and β-actin (A2228, SIGMA) were
used to detect the indicated proteins. Bands were visualized
with the use of horseradish peroxidase-coupled secondary
anti-mouse or anti-rabbit antibody (Cell Signaling
Technology). Immunoreactivity of protein was detected with
the use of chemiluminescence, and images were captured with
a ChemiDoc MP Imaging System (Bio-Rad Labs). To obtain
quantitative results, immunoblots were scanned with the use
of SynGene Gene Tools version 4.03.0 (Synoptics Ltd.
Beacon House, Nuffield Road Cambridge, CB4 1TF, UK).
Densitometry was performed to normalize to β-actin protein
level. Presented are representative membranes of at least three
independent experiments.
Densitometry analysis
Densitometry of western blot analysis was performed with the
use of SynGene Gene Tools version 4.03.0 (Synoptics Ltd.
Beacon House, Nuffield Road Cambridge, CB4 1TF, UK)
and the results were normalized to β-actin protein level.
Presented are representative membranes of at least three inde-
pendent experiments with similar results.
Statistics
Statistical analyses were performed using one-way ANOVA
with post-hoc Dunett test (Statistica 12.0 StatSoft). The statis-
tical significance is presented in Figures.
Results
Cytotoxicity assay
In all examined melanoma cell lines, inhibitors:: AKT –
MK-2206 (2 μM), MEK – AS-703026 (10 μM), PI3K –
LY294002 (20 μM), ERK1/2 – U0126 (10 μM), mTOR –
everolimus (20 nM, 2 μM, 5 μM and 10 μM) showed no
cytotoxicity effect in the 24 h of treatment. LDH activity in
the culture medium in no case exceeded 3,8%; however,
after 72 h treatment, the effect of cytotoxicity was noticed
for combinations of inhibitors: AS-703026 with LY294002
(13%), and MK-2206 with U126 (11%). Increased lactate
dehydrogenase activity for the WM266–4 cell line for
combination of inhibitors: AS-703026 and MK-2206
(7,1%) was also observed.
Expression Bcl-2 family pro-survival protein
The current study focuses on the comparison of the influence
of mTOR inhibitor everolimus, and proteins kinase inhibitors:
AKT - MK-2206, PI3K - LY294002 and ERK1/2 - U126 and
their combinations on the expression of pro-survival proteins:
p-Bcl-2 (S70), p-Bcl-2 (T56), Bcl-2, Bcl-xL, and Mcl-1 in
metastatic (WM 266–4) and primary (WM 115) melanoma
cell lines (Fig. 1).
The protein kinase inhibitors, when used individually, pro-
duced a decrease in the expression of pro-survival proteins,
whereas, their combinations had significantly more pro-
nounced effects (Fig. 1).
The most visible effect of melanoma cells treatment
with single inhibitor on the protein expression level of p-
Bcl-2 (S70) and p-Bcl-2 (T56) was observed after incuba-
tion with MEK inhibitor - AS-703026 or PI3K inhibitor -
LY294002, slightly weaker being that for ERK1/2 inhibitor
- U126 or AKT - MK-2206 (Fig.1). The expression level of
total Bcl-2 also decreased in WM 266–4 and WM 115 cell
lines. Additionally, AS-703026 inhibitor significantly re-
duced the expression level of Bcl-xL (by about 70%) in
WM 266–4 (Fig. 1b).
Moreover, the combinations of inhibitors significantly
affected the expression level of analysed pro-survival pro-
teins. The most significant, nearly 100% reduction, was
observed in WM 266–4, and 80% decrease in WM 115
after their treatment with combination of MEK inhibitor -
AS-703026 and PI3K - LY294002 (Fig.1). Slightly worse
results were obtained for the combination of inhibitors:
AS-703026 with MK-2206, and MK-2206 with U126 in
both melanoma cell lines (Fig. 1).
The effect of different doses of everolimus (20 nM,
2 μM, 5 μM, and 10 μM) as well as the combination of
everolimus (20 nM and 10 μM) with AS-703026 and MK-
2206 on the expression of pro-survival proteins was also
evaluated. The most visible reduction of the expression
level of studied proteins was observed after treatment of
WM115 and WM266–4 with 10 μM everolimus. (Fig. 2).
However, its 5 μM concentration reduced Mcl-1 expres-
sion by almost 100% in WM 266–4. Addition of AS-
703026 to 10 μM everolimus contributed to the most sig-
nificant reduction of apoptotic proteins expression levels in
both melanoma cell lines where all evaluated proteins were
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reduced by more than 80%. This effect was also evident at
20 nM everolimus concentration (Fig. 2). Somewhat sur-
prisingly, a slight increase in the expression of Bcl-2, Bcl-2
(S70) and Bcl-xL in WM266–4 using a combination of
20 nM everolimus and MK-2206 was noted. The use of
AKT inhibitor – MK2206 in combination with an mTOR
inhibitor everolimus was less effective; however, the clear-
cut effect was observed at everolimus 10 μM concentra-
tion, the highest level used (Fig. 2).
Caspase-3 activity and cell proliferation in melanoma
cell lines
Investigated was also the effect of protein kinases’ inhibi-
tors: AKT – MK-2206, MEK – AS-703026, PI3K –
LY294002 and ERK1/2 – U126 and mTOR – everolimus
in a single mode, and their combinations on caspase-3 ac-
tivation and proliferation in WM266–4 and WM115 mela-
noma cell lines.
Fig. 1 Expression of pro-survival
proteins in: WM115 (a) and-
WM266–4 (b). Western blot
analysis was performed in accor-
dance with Materials and
Methods. Densitometry analyses
of western blot were performed
on raw volume (sum of intensities
of bound-volume calculated from
the area of the peak) using
SynGene Gene Tools version
4.03.0 (Synoptics Ltd. Beacon
House, Nuffield Road
Cambridge, CB4 1TF, UK).
Densitometry results were nor-
malized to control (melanoma
cells untreated with protein kinase
inhibitors). Presented are repre-
sentative of at least three inde-
pendent experiments
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The highest increases of caspase-3 activity in the case of
individually-used protein kinase inhibitors were observed for
both cell lines after application ofMEK kinase inhibitor –AS-
703026. Aweaker yet meaningful effect occurred for ERK1/2
inhibitor - U126. A few-fold, although not particularly signif-
icant, increase of caspase-3 activity was also observed for
AKT inhibitor – MK-2206 and PI3K - LY294002 (Fig. 3a).
For both melanoma cell lines, treatment with protein kinase
inhibitors was accompanied by a decrease in proliferation:
highest after the use of the AKT inhibitor - MK2206 (about
40%), and slightly smaller for inhibitors of the MAP kinase
pathway, AS-703026 or U126 (Fig. 3b).
The combination of inhibitors was accompanied by sub-
stantially higher increases of caspase-3 activity. The combina-
tion ofMEK inhibitor –AS-703026 and AKT inhibitor –MK-
2206 led to up to 35-fold increase of caspase-3 activity
(p < 0.001), whereas somewhat lower, 15-fold (p < 0.001),
was observed for the combination of the MEK inhibitor -
AS-703026 and PI3K inhibitor - LY294002 (p < 0.001). Still
a high, but much lower increase was noticed for the
Fig. 2 The effect of treatment of
melanoma cells with everolimus
on expression of pro-survival Bcl-
2 family protein. Western blot
analysis of: WM115 (a) and-
WM266–4 (b) melanoma cell
lines. Densitometry analyses of
western blot were performed on
raw volume (sum of intensities of
bound-volume calculated from
the area of the peak) using
SynGene Gene Tools version
4.03.0 (Synoptics Ltd. Beacon
House, Nuffield Road
Cambridge, CB4 1TF, UK).
Densitometry results were nor-
malized to control (melanoma
cells untreated with protein kinase
inhibitors). Presented are repre-
sentative of at least three inde-
pendent experiments
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combination of inhibitors: ERK1/2 - U126 with AKT- MK-
2206 (p < 0.001) (Fig. 3a). 48 h treatment yielded a higher
increase of caspase-3 activity in comparison to 24 h treatment
in each case of inhibition, except for the use of the combina-
tion of inhibitors in lineWM266–4, suggesting faster caspase-
3 activation in this cell line (Fig. 3a).
In the case of proliferation, the greatest decrease was ob-
served for the combination of inhibitors: MK-2206 with U126
for WM266–4 cell line (about 63%), and AS-703026 with
MK-2206 for WM115 cell line (about 55%) (Fig. 3b).
In addition, the effect of mTOR inhibitor everolimus on
caspase-3 activity and proliferation was studied in the range
between 20 nM and 10 μM concentration. As the inhibitor
concentration increased, so did caspase-3 activity in both cell
lines, reaching the highest value of about 10-fold increase
relative to the control (p < 0.001) for the highest tested con-
centration of everolimus - 10 μM (Fig. 4a). The use of a
mTOR inhibitor everolimus (10 μM) in combination with
MEK one – AS-703026 resulted in approximately 25-fold
increase of caspase-3 activity (p < 0.001). Slightly lower, 15-
fold effect (p < 0.001), was observed for 20 nM concentration
of everolimus (Fig. 4b).
In contrast, cell proliferation decreased with increasing
everolimus concentration regardless of the mode of its use:
individual or in combinations. 10 μM everolimus combined
with the MK-2206 inhibitor led to a decrease of proliferation
(about 55%), and to a comparable effect for the combination
with MEK inhibitor - AS-703026 (Fig. 4b).
DNA fragmentation ELISA assay - detection
of apoptosis
In order to verify apoptosis induction in the selected samples
that were assayed for caspase-3 activity, the cell death detec-
tion ELISA assay which reflects DNA fragmentation in apo-
ptotic cells was performed. As demonstrated in Fig. 5a, in the
case of WM115 melanoma cells, none of the inhibitors used
individually was considerably effective in apoptosis triggering
except MEK inhibitor AS-703026, which led to about 4-fold
(p < 0.01) enrichment in fragmented DNA content.
The highest level of DNA apoptotic degradation was ob-
served in response to concurrent application of MEK inhibitor
- AS-703026 with AKT kinase inhibitor – MK-2206 as well
as mTOR inhibitor everolimus with MEK inhibitor- AS-
703026 (Fig. 5a). It manifested by significant increase in ab-
sorbance value as compared to an untreated sample, with the
enrichment factor (EF; calculated to estimate the fold increase
of DNA fragmentation in treated samples with reference to
Fig. 3 The effect of protein kinase inhibitors on caspase-3 activity and
cell proliferation in WM115 and WM266–4 melanoma cell lines. The
caspase-3 activity (a) and cell proliferation - crystal violet assay (b) were
calculated frommean values of three independent experiments. Statistical
analyses were performed using one-way ANOVA with post-hoc Dunett
test (Statistica 12.0 StatSoft); significant difference: (*) p < 0.05, (**)
p < 0.01, (***) p < 0.001
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control one) reaching 13,5 (p < 0.001); 11,7 (p < 0.001) and
11,3 (p < 0.001) for MEK inhibitor – AS-703026 combined
with AKT kinase inhibitor – MK-2206, 20 nM everolimus
combined with MEK inhibitor –AS-703026 and 2 μM evero-
limus combined with MEK inhibitor – AS-703026, respec-
tively. The data seem to suggest a synergistic effect of the
applied agents. Unexpectedly, further increase of everolimus
concentration in combination with AS-703026, both to 5 μM
as well as to 10 μM was not followed by enhancement of
apoptosis, showing even lower EF (8,0 (p < 0.001) and 9, 6
(p < 0.001) respectively).
Combination of mTOR inhibitor everolimus with AKT
kinase inhibitor – MK-2206 was about 2-fold, less effective
in comparison to everolimus andMEK inhibitor - AS-703026.
Independently of everolimus concentration (2, 5, 10 μM), the
EF value oscillated around 4. An exception was the combina-
tion with the lowest everolimus concentration (20 nM), in
which case the EF value reached 5,9 (p < 0.001).
Similarly, in the case of WM266–4 melanoma cells (Fig.
5b), each of the inhibitors used individually was hardly effec-
tive in apoptosis induction, with the exception of MEK inhib-
itor – AS-703026, as manifested by high EF value (~35,
p < 0.001). Nevertheless, combining MEK inhibitor – AS-
703026 with AKT kinase inhibitor – MK-2206 did not result
in such a significant enhancement as observed in WM115
cells line (Fig. 5b).
The most potent apoptosis induction was observed follow-
ing concurrent application of 20 nM everolimus with MEK
inhibitor – AS-703026, the EF of which equalled 163,3
(p < 0.001), which strongly suggests their synergistic coopera-
tion (Fig. 5b). Surprisingly, a further increase of everolimus
concentration (2–10 μM) led rather to a considerable decrease
of DNA fragmentation in those cells. Still, the EF values were
remarkably high (136.8–68,5; p < 0.001). The effectiveness of
all combinations with AKT kinase inhibitor – MK-2206 was
similar, independently of the type and concentration of the ac-
companying inhibitor and was manifested by high EF value in
the range of 70–97 (p < 0.001) (Fig. 5b). Besides MEK inhib-
itor –AS-703026 and AKT kinase inhibitor –MK-2206, all the
other combinations seem to indicate synergistic effects on apo-
ptosis induction in WM266–4 melanoma cells (Fig. 5b).
Discussion
Activation of PI3K/AKT and mTOR pathways is the main
development mechanism in many types of cancer, therefore
their inhibitors are a promising target in the search for new
Fig. 4 The effect of everolimus on caspase-3 activity and cell prolifera-
tion in: WM115 and WM266–4 melanoma cell lines. The effect of
caspase-3 activity (a) and cell proliferation - crystal violet assay (b) were
calculated frommean values of three independent experiments. Statistical
analyses were performed using one-way ANOVA with post-hoc Dunett
test (Statistica 12.0 StatSoft); significant difference: (*) p < 0.05, (**)
p < 0.01, (***) p < 0.001
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treatment strategies (Woo et al. 2017). However, the modest
antitumour effect of single-agent therapies suggests a need
for drug combinations which could reduce their concentra-
tions without the loss of activity in the pursuit of superior
clinical responses.
Many literature reports (Ji et al. 2017; Woo et al. 2017)
confirm the antitumour efficacy of mTOR inhibitor –
rapamycin or another rapalog in combination with highly se-
lective AKT inhibitor –MK2206 in inhibition of proliferation,
tumour growth and induction of apoptosis in many types of
cancers such as: lymphoblastic leukemia, cholangiocarcinoma,
hepatocellular carcinoma, neuroblastoma, gastric cancer, and
thyroid cancer.
Our previous studies (Ciołczyk-Wierzbicka and Laidler
2018; Ciołczyk-Wierzbicka et al. 2018) regarding the treat-
ment of melanoma cells with mTOR inhibitors, found that
both rapamycin and everolimus had a significant impact on
cell cycle regulation, cell proliferation, and invasive potential.
We recently demonstrated that treatment of various mela-
noma cells with low concentration (5 nM) of mTOR inhibitor
everolimus resulted in significantly reduced cell proliferation
and diminished number of cancer cells (Ciołczyk-Wierzbicka
Fig. 5 The effect of protein kinase inhibitors on melanoma cell apoptosis
- WM115 (a) and WM266–4 (b). Apoptosis was detected as photometric
enzyme-immunoassay for the qualitative and quantitative in vitro deter-
mination of cytoplasmic histone-associated-DNA-fragments (mono- and
oligonucleosomes). Effect of protein kinase inhibitors and their combina-
tions on apoptosis induction evaluated by the mean of DNA fragmenta-
tion ELISA assay after 24 h treatment of melanoma cells. Error bars
represent SD. The enrichment factor (EF) was calculated to estimate the
fold increase of DNA fragmentation in treated samples with reference to
control one. The graphs present mean values of representative experi-
ments performed in duplicates. Statistical analyses were performed using
one-way ANOVA with post-hoc Dunett test (Statistica 12.0 StatSoft);
significant difference: (*) p < 0.05, (**) p < 0.01, (***) p < 0.001
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et al. 2018). It also led to the reduction of metalloproteinase’s
(MMPs) activity, as well as reduced invasion, especially when
everolimus was used in combination with PI3K/AKTorMEK
inhibitors (Ciołczyk-Wierzbicka and Laidler 2018).
The promising preliminary results regarding the use of the
mTOR inhibitor everolimus led to the continuation of research
on the effects of this agent on pro-survival Bcl-2 family pro-
teins expression. Caspase-3 activity, proliferation, and induc-
tion of apoptosis in melanoma cells.
Expression of pro-survival Bcl-2 family proteins,
caspase-3 activity and reduction of cell proliferation
Resistance to apoptosis is an important hallmark of melanoma
(Grazia et al. 2014). Enhanced apoptotic cell death is mani-
fested, among others, by: activation of caspase-3, activation
pro-apoptotic proteins, and down-regulation of pro-survival
protein such as of Bcl-2 and Mcl-1 (Grazia et al. 2014).
Observed was a significant decrease in the expression of
studied pro-survival Bcl-2 family proteins: p-Bcl-2 (Ser70),
p-Bcl-2 (Thr56), Bcl-2, Bcl-xl, and Mcl-1 after the use of pro-
tein kinase inhibitors, which is particularly meaningful when
using their combinations. A slight increase in the expression of
Bcl-2 and Bcl-2 phosphorylated at serine 70 in the WM266–4
cells after simultaneous blocking of the kinase mTOR pathway
(20 nM everolimus) and AKT kinase (MK-2206) may indicate
the emergence of drug resistance mechanisms. Observations
based on acute myeloid leukaemia [Konopleva et al. 2006]
suggest that Mcl-1 expression and basal Bcl-2 phosphorylation
may contribute to the drug resistance. During our studies, a
decrease in Mcl-1 protein was observed, especially after inhi-
bition of the MEK kinase inhibitor AS-703026, both alone and
together with the mTOR - everolimus inhibitor.
In the case of single protein kinase inhibitors, a significant
increase in caspase-3 activity was observed after the use of the
MEK kinase inhibitor AS-703026; slightly less profound yet
similar effect occurred for the ERK1/2 inhibitor - U126. The
increase of caspase-3 activity was also observed for the AKT
– MK-2206 and PI3K - LY294002 inhibitors.
According to Kim et al. (2010), inhibition of proliferation
induced by AS-703026 was mediated by G0-G1 cell cycle
arrest and was accompanied by induced apoptosis via
caspase-3 and Poly ADP ribose polymerase (PARP) cleavage
inmultiple myeloma cells, both in the presence and absence of
bone marrow stromal cells. Results obtained by Park et al.
(2013) suggest that the treatment of malignant melanoma cells
(harbouring mutation V600E and resistance to B-RAF inhib-
itors) with a combination of B-RAF – PLX4032 and MEK –
AS-703026 inhibitors significantly induced apoptosis and
caspase-3 expression. The use of each of these agents alone
was not marked with high efficiency (Park et al. 2013).
Here, the use of combinations of inhibitors gave signifi-
cantly better results than the use of single inhibitors in terms
of suppressing the expression of pro-survival proteins, in-
creasing activity of caspase-3, and decreasing cell prolifera-
tion. The observed increase in caspase-3 activity was signifi-
cantly higher after 48 h treatment, except for the use of the
combination of PI3K/AKT and MEK inhibitors in WM266–4
cell line, for which this combination of inhibitors led to ele-
vated LDH activity. In this cell line, observed was a higher
increase in caspase-3 activity in a shorter period (24 h), which
indicates a faster activation of caspase-3 in this cell line. All
this could suggest that the combination of PI3K/AKT and
MEK inhibitors caused lysis of WM266–4 cells in addition
to their apoptosis.
The treatment of melanoma cells with mTOR inhibitor
everolimus (20 nM to 10 μM concentrations) gave promising
results, similar to those regarding the effect of this inhibitor on
the cell cycle, proliferation, and invasiveness (Ciołczyk-
Wierzbicka and Laidler 2018; Ciołczyk-Wierzbicka et al.
2018). The low concentration of the mTOR inhibitor everoli-
mus (20 nM) led to a significant decrease in the expression of
all pro-survival Bcl-2 family proteins.
The results obtained by Du et al. (2018) show that everoli-
mus treatment decreased expression of Bcl-2 gene in breast
cancer cells.
The use of a combination of mTOR inhibitor – rapamycin
and AKT inhibitor – MK-2206 has been described by many
research groups that reported a reduction of cell growth,
blockade of cell cycle progression, and enhanced apoptosis
in different melanoma models (humans, murine and canine)
(Grazia et al. 2014).
Numerous data show decreased cell proliferation and
increased caspase-3 activity after the use of mTOR inhib-
itors in many cases of tumours such as pancreatic (Peng
and Dou 2017), breast (Woo et al. 2017), and colon cancer
(He et al. 2016).
Here, everolimus concentration was found to remain in
inverse proportion to proliferation of melanoma cells – the
higher the former, the lower the latter. The combination of
10 μM concentration of everolimus with the MK-2206 inhib-
itor resulted in the decrease in proliferation by 55%. A slightly
lower decrease was observed for the combination with AS-
703026 inhibitor.
Apoptosis
Based on the results obtained for the inhibition of pro-survival
proteins and caspase-3 activity, the most effective protein ki-
nases inhibitors: AS-703026, MK-2206 and various concen-
trations (20 nM to 10 μM) of mTOR inhibitor everolimus
were selected with the aim of studying the apoptosis activation
in melanoma cells.
Among the single inhibitors used, theMEK inhibitor –AS-
703026 was the most effective in induction of apoptosis as
measured by caspase-3 activation. Similar results were
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obtained for patients with multiple myeloma (Kim et al. 2010;
Kim et al. 2017). Results of the study based on human mela-
noma cell line with B-RAF V600E mutation that are resistant
to B-RAF inhibitors confirmed the efficacy of the AS-703026
inhibitor in the induction of apoptosis and its particular effi-
cacy in combination with the B-RAF inhibitor - PLX4032
(Park et al. 2013).
Herein demonstrated is the fact that everolimus in 10 μM
concentration was even more effective than the AKT inhibitor
–MK-2206 for the primary melanoma cell line –WM115, while
low concentrations of the everolimus induced apoptosis in mel-
anoma cells at a very low level. Everolimus (and another
rapalogs) induces apoptosis in a variety of tumours cells: pancre-
atic cancer (Peng and Dou 2017), ovarian cancer (Guo et al.
2016), colon cancer (He et al. 2016), breast cancer (Du et al.
2018), N-RAS mutant neuroblastoma cell lines (Kiessling et al.
2016), and T cell leukemia/lymphoma in long-term treatment
(Darwiche et al. 2011), however in some tumours its high con-
centration stimulates a caspase-independent pathway – autopha-
gy cell death (Nikoletopoulou et al. 2013; Lui et al. 2016).
Autophagy is the process related to cancer progression
(Mowers et al. 2017). High level of autophagy can be observed
in some rapidly growing cells (Neufeld 2012) and in cells losing
cellular adhesion (Dower et al. 2018). Autophagy may also sen-
sitize tumour cells to anticancer drugs (Paquette et al. 2018). The
effect of treatment of WM266–4 cells with 10 μM everolimus
suggests that high concentration of this rapalog, similarly to PI3K
kinase inhibitors and other activators (Milinkovic et al. 2018),
might have induced autophagy in the studied metastatic cells
(WM266–4).
It is noteworthy that the very low concentrations of the
everolimus inhibitor (20 nM) in combination with the MEK
inhibitor - AS-703026 led to very significant apoptotic effects.
The results presented by Zeng et al. (2018) show that the com-
bination of everolimus andAZD6244 – a highly selective ERK
inhibitor, significantly enhanced apoptosis and impaired the
viability of renal carcinoma cells, while high concentrations
of everolimus alone induce autophagy in these cells.
Kiessling et al. (2016) showed thatmTOR inhibitor everolimus
in single mode use reduces cell growth and leads to apoptosis
in N-RASmutant neuroblastoma cell lines, and in combination
with MEK inhibitor produced a synergistic effect and could be
important in future clinical studies.
The results obtained by He et al. (2016) regarding the use
of high concentrations of everolimus (10-25 μM) in colon
cancer cells with the BRAF V600E and K-RAS mutation
showed that they are unlikely to respond to monotherapy
targeting mTOR inhibitor, but might benefit from combina-
tion therapy with PI3K, RAF or MEK inhibitors.
Results of studies from many centres on a panel of human
cancer cell lines of different histological origin confirmed the
role of PTEN status in determining pharmacological interac-
tions between RAF/MEK and PI3K/AKT/mTOR pathways
inhibitors (Weeber et al. 2017; Sathe et al. 2018; Milella
et al. 2017). PTEN-loss allowed effective prediction of syner-
gistic inhibitory growth interactions between RAF/MEK and
PI3K/AKT/mTOR inhibitors (Milella et al. 2017).
A similar, but lower effect was also observed here for the
combination of AKT inhibitor – MK-2206 and everolimus.
This combination was more effective in inhibiting melanoma
cell proliferation. Our recent study showed that this combina-
tion of protein kinase inhibitors had a very promising effect on
inhibiting the invasiveness and activity of metalloproteinase 2
and 9 (Ciołczyk-Wierzbicka and Laidler 2018).
MK-2206, a potent oral allosteric AKT inhibitor that en-
hances the antitumour potency of chemotherapeutic agents (Ji
et al. 2017), had no effect on normal peripheral blood mono-
nuclear cells, but induced G1-phase arrest and apoptosis in
leukemia cells (Lu et al. 2015), and induction of apoptosis
by combined treatment of bufalin in multiple myeloma cells
(Xiang et al. 2017).
The herein reported nanomolar concentration of mTOR
inhibitor everolimus in the combination with inhibitor of
MAP kinase (AS-703026) or AKT kinase (MK-2206) path-
way are sufficient to induce apoptosis, and reduce prolifera-
tion and invasiveness in melanoma cells. The result seems
very important and promising on account of the low concen-
trations of inhibitors. One can hope that such an approach will
find recognition and application in the near future.
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